TY - STD TI - Arbat S, et al. Study of factors affecting mortality in ILD cases over 2 years. Eur Respir J. 2016;48(suppl 60) ID - ref1 ER - TY - JOUR AU - Hutchinson, J. PY - 2015 DA - 2015// TI - Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review JO - Eur Respir J VL - 46 UR - https://doi.org/10.1183/09031936.00185114 DO - 10.1183/09031936.00185114 ID - Hutchinson2015 ER - TY - STD TI - Kärkkäinen M, et al. Course of disease and cause of death in patients with idiopathic pulmonary fibrosis in eastern Finland. Eur Respir J. 2015;46(suppl 59) ID - ref3 ER - TY - JOUR AU - Rogliani, P. PY - 2016 DA - 2016// TI - Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis JO - Pulm Pharmacol Ther VL - 40 UR - https://doi.org/10.1016/j.pupt.2016.07.009 DO - 10.1016/j.pupt.2016.07.009 ID - Rogliani2016 ER - TY - JOUR AU - Lavorini, F. AU - Fontana, G. A. AU - Usmani, O. S. PY - 2014 DA - 2014// TI - New inhaler devices-the good, the bad and the ugly JO - Respiration VL - 88 UR - https://doi.org/10.1159/000363390 DO - 10.1159/000363390 ID - Lavorini2014 ER - TY - JOUR AU - Okuda, R. PY - 2016 DA - 2016// TI - Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis: a prospective, single-arm study JO - Respir Investig VL - 54 UR - https://doi.org/10.1016/j.resinv.2015.10.001 DO - 10.1016/j.resinv.2015.10.001 ID - Okuda2016 ER - TY - JOUR AU - Fusiak, T. AU - Smaldone, G. C. AU - Condos, R. PY - 2015 DA - 2015// TI - Pulmonary fibrosis treated with inhaled interferon-gamma (IFN-γ) JO - J Aerosol Med Pulm Drug Deliv VL - 28 UR - https://doi.org/10.1089/jamp.2015.1221 DO - 10.1089/jamp.2015.1221 ID - Fusiak2015 ER - TY - JOUR AU - Markart, P. PY - 2010 DA - 2010// TI - Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis JO - J Aerosol Med Pulm Drug Deliv VL - 23 UR - https://doi.org/10.1089/jamp.2009.0780 DO - 10.1089/jamp.2009.0780 ID - Markart2010 ER - TY - JOUR AU - Strickland, N. H. PY - 1993 DA - 1993// TI - Cause of regional ventilation-perfusion mismatching in patients with idiopathic pulmonary fibrosis: a combined CT and scintigraphic study JO - AJR Am J Roentgenol VL - 161 UR - https://doi.org/10.2214/ajr.161.4.8372745 DO - 10.2214/ajr.161.4.8372745 ID - Strickland1993 ER - TY - JOUR AU - Ogawa, Y. PY - 1997 DA - 1997// TI - Regional ventilation-perfusion mismatch in interstitial pneumonia correlation between scintigraphy and CT JO - Clin Nucl Med VL - 22 UR - https://doi.org/10.1097/00003072-199703000-00006 DO - 10.1097/00003072-199703000-00006 ID - Ogawa1997 ER - TY - JOUR AU - Suga, K. PY - 2009 DA - 2009// TI - Characteristic crescentic subpleural lung zones with high ventilation (V)/perfusion (Q) ratios in interstitial pneumonia on V/Q quotient SPECT JO - Nucl Med Commun VL - 30 UR - https://doi.org/10.1097/MNM.0b013e328330571d DO - 10.1097/MNM.0b013e328330571d ID - Suga2009 ER - TY - JOUR AU - Hirani, N. PY - 2016 DA - 2016// TI - TD139, A Novel Inhaled Galectin-3 Inhibitor for The Treatment of Idiopathic Pulmonary Fibrosis (IPF). Results from The First in (IPF) Patients Study JO - QJM VL - 109 ID - Hirani2016 ER - TY - JOUR AU - Usmani, O. S. AU - Biddiscombe, M. F. AU - Barnes, P. J. PY - 2005 DA - 2005// TI - Regional lung deposition and bronchodilator response as a function of β2-agonist particle size JO - Am J Respir Crit Care Med VL - 172 UR - https://doi.org/10.1164/rccm.200410-1414OC DO - 10.1164/rccm.200410-1414OC ID - Usmani2005 ER - TY - JOUR AU - Hindle, M. AU - Chrystyn, H. PY - 1992 DA - 1992// TI - Determination of the relative bioavailability of salbutamol to the lung following inhalation [see comments] JO - Br J Clin Pharmacol VL - 34 UR - https://doi.org/10.1111/j.1365-2125.1992.tb05921.x DO - 10.1111/j.1365-2125.1992.tb05921.x ID - Hindle1992 ER - TY - JOUR AU - Hindle, M. AU - Newton, D. AU - Chrystyn, H. PY - 1993 DA - 1993// TI - Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung JO - Thorax VL - 48 UR - https://doi.org/10.1136/thx.48.6.607 DO - 10.1136/thx.48.6.607 ID - Hindle1993 ER - TY - JOUR AU - Raghu, G. PY - 2011 DA - 2011// TI - An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management JO - Am J Respir Crit Care Med VL - 183 UR - https://doi.org/10.1164/rccm.2009-040GL DO - 10.1164/rccm.2009-040GL ID - Raghu2011 ER - TY - JOUR AU - Assayag, D. PY - 2015 DA - 2015// TI - The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis JO - Respir Med VL - 109 UR - https://doi.org/10.1016/j.rmed.2015.06.012 DO - 10.1016/j.rmed.2015.06.012 ID - Assayag2015 ER - TY - JOUR AU - Usmani, O. S. PY - 2004 DA - 2004// TI - Characterization of the generation of radiolabeled monodisperse albuterol particles using the spinning-top aerosol generator JO - J Nucl Med VL - 45 ID - Usmani2004 ER - TY - JOUR AU - Biddiscombe, M. F. AU - Usmani, O. S. AU - Barnes, P. J. PY - 2003 DA - 2003// TI - A system for the production and delivery of monodisperse salbutamol aerosols to the lungs JO - Int J Pharm VL - 254 UR - https://doi.org/10.1016/S0378-5173(03)00032-2 DO - 10.1016/S0378-5173(03)00032-2 ID - Biddiscombe2003 ER - TY - JOUR AU - Newman, S. PY - 2012 DA - 2012// TI - Standardization of techniques for using planar (2D) imaging for aerosol deposition assessment of orally inhaled products JO - J Aerosol Med Pulm Drug Deliv VL - 25 UR - https://doi.org/10.1089/jamp.2012.1Su4 DO - 10.1089/jamp.2012.1Su4 ID - Newman2012 ER - TY - JOUR AU - Du, X. -. L. PY - 2002 DA - 2002// TI - Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers JO - Acta Pharmacol Sin VL - 23 ID - Du2002 ER - TY - JOUR AU - Elers, J. PY - 2010 DA - 2010// TI - Blood and urinary concentrations of salbutamol in asthmatic subjects JO - Med Sci Sports Exerc VL - 42 UR - https://doi.org/10.1249/MSS.0b013e3181b2e87d DO - 10.1249/MSS.0b013e3181b2e87d ID - Elers2010 ER - TY - JOUR AU - Horan, G. S. PY - 2008 DA - 2008// TI - Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without exacerbating inflammation JO - Am J Respir Crit Care Med VL - 177 UR - https://doi.org/10.1164/rccm.200706-805OC DO - 10.1164/rccm.200706-805OC ID - Horan2008 ER - TY - JOUR AU - Lipson, K. E. PY - 2012 DA - 2012// TI - CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis JO - Fibrogenesis Tissue Repair VL - 5 UR - https://doi.org/10.1186/1755-1536-5-1 DO - 10.1186/1755-1536-5-1 ID - Lipson2012 ER - TY - JOUR AU - Edwards, C. D. PY - 2016 DA - 2016// TI - Development of a novel quantitative structure-activity relationship model to accurately predict pulmonary absorption and replace routine use of the isolated perfused respiring rat lung model JO - Pharm Res VL - 33 UR - https://doi.org/10.1007/s11095-016-1983-4 DO - 10.1007/s11095-016-1983-4 ID - Edwards2016 ER - TY - JOUR AU - Bäckman, P. PY - 2014 DA - 2014// TI - Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product JO - Clin Pharmacol Therap VL - 95 UR - https://doi.org/10.1038/clpt.2014.27 DO - 10.1038/clpt.2014.27 ID - Bäckman2014 ER - TY - JOUR AU - Patton, J. S. PY - 2010 DA - 2010// TI - The particle has landed--characterizing the fate of inhaled pharmaceuticals JO - J Aerosol Med Pulm Drug Deliv VL - 23 ID - Patton2010 ER - TY - JOUR AU - Cottin, V. AU - Maher, T. PY - 2015 DA - 2015// TI - Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis JO - Eur Respir Rev VL - 24 UR - https://doi.org/10.1183/09059180.00011514 DO - 10.1183/09059180.00011514 ID - Cottin2015 ER - TY - JOUR AU - Biddiscombe, M. F. PY - 2011 DA - 2011// TI - Comparing lung regions of interest in gamma scintigraphy for assessing inhaled therapeutic aerosol deposition JO - J Aerosol Med Pulm Drug Deliv VL - 24 UR - https://doi.org/10.1089/jamp.2010.0845 DO - 10.1089/jamp.2010.0845 ID - Biddiscombe2011 ER - TY - JOUR AU - Mukhopadhyay, S. PY - 1994 DA - 1994// TI - The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis JO - Respir Med VL - 88 UR - https://doi.org/10.1016/S0954-6111(05)80348-8 DO - 10.1016/S0954-6111(05)80348-8 ID - Mukhopadhyay1994 ER - TY - JOUR AU - Fairfax, A. PY - 1981 DA - 1981// TI - Pulmonary disorders associated with Sjögren’s syndrome JO - QJM VL - 50 ID - Fairfax1981 ER - TY - JOUR AU - Bando, M. PY - 2010 DA - 2010// TI - Long-term efficacy of inhaled N-acetylcysteine in patients with idiopathic pulmonary fibrosis JO - Intern Med VL - 49 UR - https://doi.org/10.2169/internalmedicine.49.4011 DO - 10.2169/internalmedicine.49.4011 ID - Bando2010 ER - TY - JOUR AU - Homma, S. PY - 2012 DA - 2012// TI - Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis JO - Respirology VL - 17 UR - https://doi.org/10.1111/j.1440-1843.2012.02132.x DO - 10.1111/j.1440-1843.2012.02132.x ID - Homma2012 ER - TY - JOUR AU - Muramatsu, Y. PY - 2016 DA - 2016// TI - Effect of inhaled N-acetylcysteine monotherapy on lung function and redox balance in idiopathic pulmonary fibrosis JO - Respir Investig VL - 54 UR - https://doi.org/10.1016/j.resinv.2015.11.004 DO - 10.1016/j.resinv.2015.11.004 ID - Muramatsu2016 ER - TY - JOUR AU - Diaz, K. T. PY - 2012 DA - 2012// TI - Delivery and safety of inhaled interferon-gamma in idiopathic pulmonary fibrosis JO - J Aerosol Med Pulm Drug Deliv VL - 25 UR - https://doi.org/10.1089/jamp.2011.0919 DO - 10.1089/jamp.2011.0919 ID - Diaz2012 ER - TY - JOUR AU - Skaria, S. D. PY - 2015 DA - 2015// TI - Inhaled interferon and diffusion capacity in idiopathic pulmonary fibrosis (IPF) JO - Sarcoidosis Vasc Diffuse Lung Dis VL - 32 ID - Skaria2015 ER - TY - JOUR AU - Hochhaus, G. AU - Möllmann, H. PY - 1992 DA - 1992// TI - Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol JO - Int J Clin Pharmacol Ther Toxicol VL - 30 ID - Hochhaus1992 ER - TY - JOUR AU - Newman, S. P. PY - 1981 DA - 1981// TI - Deposition of pressurised aerosols in the human respiratory tract JO - Thorax VL - 36 UR - https://doi.org/10.1136/thx.36.1.52 DO - 10.1136/thx.36.1.52 ID - Newman1981 ER - TY - JOUR AU - Hindle, M. AU - Chrystyn, H. PY - 1994 DA - 1994// TI - Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices JO - Thorax VL - 49 UR - https://doi.org/10.1136/thx.49.6.549 DO - 10.1136/thx.49.6.549 ID - Hindle1994 ER - TY - JOUR AU - Hindle, M. PY - 1997 DA - 1997// TI - Relative bioavailability of salbutamol to the lung following inhalation via a novel dry powder inhaler and a standard metered dose inhaler JO - Br J Clin Pharmacol VL - 43 UR - https://doi.org/10.1046/j.1365-2125.1997.00564.x DO - 10.1046/j.1365-2125.1997.00564.x ID - Hindle1997 ER - TY - JOUR AU - Chege, J. AU - Chrystyn, H. PY - 1994 DA - 1994// TI - Volumatic usage: some generic salbutamol metered dose inhalers can be used JO - Thorax VL - 49 UR - https://doi.org/10.1136/thx.49.11.1162 DO - 10.1136/thx.49.11.1162 ID - Chege1994 ER - TY - JOUR AU - Silkstone, V. PY - 2000 DA - 2000// TI - Relative bioavailability of salbutamol to the lung following inhalation when administration is prolonged JO - Br J Clin Pharmacol VL - 50 UR - https://doi.org/10.1046/j.1365-2125.2000.00255.x DO - 10.1046/j.1365-2125.2000.00255.x ID - Silkstone2000 ER -